Ownership history in UBS Group AG · 7 quarters on record
This page tracks every 13F SEC filing in which UBS Group AG reported a position in TOURMALINE BIO INC (TRML). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | REDUCED | 178,371 | -51,029 | -22.2% | 0.00% | $8.5M | — |
| 2025 Q2 | ADDED | 229,400 | +5,717 | +2.6% | 0.00% | $3.7M | — |
| 2025 Q1 | ADDED | 223,683 | +34,452 | +18.2% | 0.00% | $3.4M | — |
| 2024 Q4 | ADDED | 189,231 | +177,385 | +1497.4% | 0.00% | $3.8M | — |
| 2024 Q3 | ADDED | 11,846 | +2,146 | +22.1% | 0.00% | $305K | — |
| 2024 Q2 | ADDED | 9,700 | +6,879 | +243.8% | 0.00% | $125K | — |
| 2024 Q1 | INITIATED | 2,821 | — | — | 0.00% | $65K | — |
As of 2025 Q3 — sorted by position size